Work

Case report: Eczematous adverse drug reaction after selpercatinib treatment

Year: 2024

Type: article

Abstract: This study reports a 50-year-old patient presented with eczematous drug-eruption induced by selpercatinib after the treatment of non-small cell lung cancer (NSCLC). The patient has symmetric erythematous papules and plaques all over the body with dry, scaly skin accompanied by severe pruritus and visible scarring. After systemic treatment with glucocorticoids, the patient' skin lesions were reduced well. Currently, the medical literature on the incidence of selpercatinib-induced cutaneous eczematous reactions and their clinical management is scarce. Therefore, this study provides novel evidence for the treatment of selpercatinib-induced cutaneous eczematous reactions.

Source: Frontiers in Oncology

DOI: 10.3389/fonc.2024.1475541

Authors: Bingrun Li, Peng Cao, Wenjing Xu, Litao Zhang

Institution: Tianjin University of Traditional Chinese Medicine

Language: English

Topic: Chemotherapy-related skin toxicity

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,295